Amir Ahmad Nassiri1, Monir Sadat Hakemi2, Reza Safar-Pour1, Ali Ahmadi3, Maryam Tohidi4, Babak Sharif Kashani5, Fatemeh Esfehani6, Soudabeh Alatab1. 1. Department of Nephrology, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of). 2. Department of Nephrology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of). 3. Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of). 4. Department of Pathology, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of). 5. Department of Cardiology, Massih-Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of). 6. Research Center, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of).
Abstract
OBJECTIVES: To determine the association of fibroblast growth factor 23 (FGF23) with left ventricular hypertrophy (LVH) through the assessment of left ventricular (LV) mass and left ventricular mass index (LVMI) in patients on hemodialysis, this study was done. METHODS: All patients on hemodialysis who are older than 18 years and in whom hemodialysis vintage was at least 6 months were enrolled. All patients were on hemodialysis thrice a week for 4 h using low-flux dialysis filters, polysulfone membranes, reverse osmosis purified water, and bicarbonate-base hemodialysis solution. The exclusion criteria were any respiratory illness or pulmonary infection, cigarette smoking, and the presence of pericarditis or pericardial effusion. Additionally, patients with a known coronary artery disease, any form of cardiac arrhythmias, any cardiomyopathy or severe valvular heart disease diagnosed by echocardiography, acute congestive heart failure (CHF), and acute myocardial infarction were not included. Echocardiography was conducted by an experienced operator for all the enrolled patients using the ACUSON SC2000™ ultrasound system transducer (Siemens), with a frequency bandwidth of: 1.5-3.5 MHz. Patients were considered to have LVH if the LVMI was greater than 134 g/m2 for men and greater than 110 g/m2 for women. RESULTS: A total of 61 patients (19 female and 42 male) were enrolled to the study. Mean (± SD) age of the patients was 59.6 ± 13.1 years. The median duration of hemodialysis was 23 (range: 6-120) months. The median predialysis level of FGF23 was 1,977 pg/mL (range: 155-8,870). LVH was seen in 73.8% of the patients (n = 45) and of them 66.7% were male. There was a statistically significant direct correlation between FGF23 and left ventricle diameter in end systole (LVDs) (r = 0.29, P = 0.027). However, the association of FGF23 with LV mass, LVMI, and left ventricular ejection fraction (LVEF) was not significant. CONCLUSION: This study does not show the correlation between FGF23 and LV mass in stable hemodialysis patients.
OBJECTIVES: To determine the association of fibroblast growth factor 23 (FGF23) with left ventricular hypertrophy (LVH) through the assessment of left ventricular (LV) mass and left ventricular mass index (LVMI) in patients on hemodialysis, this study was done. METHODS: All patients on hemodialysis who are older than 18 years and in whom hemodialysis vintage was at least 6 months were enrolled. All patients were on hemodialysis thrice a week for 4 h using low-flux dialysis filters, polysulfone membranes, reverse osmosis purified water, and bicarbonate-base hemodialysis solution. The exclusion criteria were any respiratory illness or pulmonary infection, cigarette smoking, and the presence of pericarditis or pericardial effusion. Additionally, patients with a known coronary artery disease, any form of cardiac arrhythmias, any cardiomyopathy or severe valvular heart disease diagnosed by echocardiography, acute congestive heart failure (CHF), and acute myocardial infarction were not included. Echocardiography was conducted by an experienced operator for all the enrolled patients using the ACUSON SC2000™ ultrasound system transducer (Siemens), with a frequency bandwidth of: 1.5-3.5 MHz. Patients were considered to have LVH if the LVMI was greater than 134 g/m2 for men and greater than 110 g/m2 for women. RESULTS: A total of 61 patients (19 female and 42 male) were enrolled to the study. Mean (± SD) age of the patients was 59.6 ± 13.1 years. The median duration of hemodialysis was 23 (range: 6-120) months. The median predialysis level of FGF23 was 1,977 pg/mL (range: 155-8,870). LVH was seen in 73.8% of the patients (n = 45) and of them 66.7% were male. There was a statistically significant direct correlation between FGF23 and left ventricle diameter in end systole (LVDs) (r = 0.29, P = 0.027). However, the association of FGF23 with LV mass, LVMI, and left ventricular ejection fraction (LVEF) was not significant. CONCLUSION: This study does not show the correlation between FGF23 and LV mass in stable hemodialysis patients.
Authors: Manish D Sinha; Charles Turner; Caroline J Booth; Simon Waller; Pernille Rasmussen; David J A Goldsmith; John M Simpson Journal: Pediatr Nephrol Date: 2015-05-15 Impact factor: 3.714
Authors: Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf Journal: JAMA Date: 2011-06-15 Impact factor: 56.272
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: J Am Soc Nephrol Date: 2011-09-07 Impact factor: 10.121
Authors: Bryan Kestenbaum; Michael C Sachs; Andy N Hoofnagle; David S Siscovick; Joachim H Ix; Cassianne Robinson-Cohen; Joao A C Lima; Joseph F Polak; Marc Blondon; John Ruzinski; Denise Rock; Ian H de Boer Journal: Circ Heart Fail Date: 2014-03-25 Impact factor: 8.790
Authors: José Alberto Navarro-García; Rafael Salguero-Bodes; Laura González-Lafuente; Laura Martín-Nunes; Elena Rodríguez-Sánchez; Teresa Bada-Bosch; Eduardo Hernández; Evangelina Mérida-Herrero; Manuel Praga; Jorge Solís; Fernando Arribas; Héctor Bueno; Makoto Kuro-O; María Fernández-Velasco; Luis Miguel Ruilope; Carmen Delgado; Gema Ruiz-Hurtado Journal: BMC Med Date: 2022-01-19 Impact factor: 8.775